Lynovex

Lynovex® (NM001) is a first-in-class orphan drug candidate for cystic fibrosis.

Patients at the centre of rare disease therapy development

Posted 13-Jan-2020

Autumn 013 2019 Rare Gene Therapy Orig

Dr Deborah O’Neil, CEO of NovaBiotics, features in the latest issue of Rare Revolution Magazine in the Patient Partners edition.

Dr O’Neil explains how early patient engagement and honest feedback shaped tailored treatments in cystic fibrosis, namely our Lynovex therapies (oral and inhaled).

The full article can be accessed here Rare Revolution Article

Lynovex® Latest

Care Cf 1 Oral Lynovex Clinical Trial Data Published

Patients at the centre of rare disease therapy development

Three Posters on New Lynovex Preclinical and Clinical Data

Novabiotics To Present New Data On Their Novel Cystic Fibrosis Drugs At The European Cf Society’S Annual Conference

Novabiotics Presenting New Data At European Cystic Fibrosis Conference